Search company, investor...
Search
Xilis company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

xilis.net

Founded Year

2019

Stage

Series A - II | Alive

Total Raised

$94M

Last Raised

$19M | 2 mos ago

About Xilis

Xilis develops a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Its technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. The company serves clients operating in the healthcare sector. It was founded in 2019 and is based in Durham, North Carolina.

Xilis Headquarters Location

801 Capitola Dr Suite 12

Durham, North Carolina, 27713,

United States

984-377-6738

ESPs containing Xilis

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Biopharma Tech

These companies use patient-derived cells and tissue samples to create structures that mimic human physiology. These solutions come in two categories. Some vendors develop organoids, which are miniaturized and simplified versions of organs and tissue structures. Other vendors insert human cells into microfluidic assays in order to emulate human physiology.

Xilis named as Highflier among 11 other companies, including Emulate, Hubrecht Organoid Technology, and CN Bio Innovations.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Xilis

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Xilis in 1 CB Insights research brief, most recently on Sep 19, 2022.

Expert Collections containing Xilis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xilis is included in 4 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest Xilis News

Xilis announces Series A extension, bringing total round to over US$89 million

Jul 15, 2022

Proceeds will enable Xilis to build its capabilities in supporting biopharma collaborations for drug discovery  Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the […] The post Xilis announces Series A extension, bringing total round to over US$89 million appeared first on Raptor Group.

  • When was Xilis founded?

    Xilis was founded in 2019.

  • Where is Xilis's headquarters?

    Xilis's headquarters is located at 801 Capitola Dr, Durham.

  • What is Xilis's latest funding round?

    Xilis's latest funding round is Series A - II.

  • How much did Xilis raise?

    Xilis raised a total of $94M.

  • Who are the investors of Xilis?

    Investors of Xilis include Pear VC, Mubadala Capital, Alix Ventures, Google Ventures, Felicis and 11 more.

  • Who are Xilis's competitors?

    Competitors of Xilis include KIYATEC.

You May Also Like

Flamma Logo
Flamma

Flamma specializes in the manufacture of active ingredients and intermediates for the pharmaceutical, nutraceutical and cosmetic industries.

O
Ocimum Biosolutions

Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

V
Virmatics

Virmatics is a bioinformatics software company developing efficient, and automated tools for biomedical researchers. Their software aims to give researchers the ability to plan experiments and record, store, and analyze data with unparalleled flexibility. Virmatics has been a member of the incubator since Fall 2004.

R
Rhenovia Pharma

Rhenovia Pharma is a French biotechnology company founded in 2007 by an international team that brings together managers from large pharmaceutical companies and world experts in neuroscience and nervous system modeling. The company is a provider in the application of biosimulation in the prevention and treatment of neurological, neurodegenerative and psychiatric disorders and diseases.

KIYATEC Logo
KIYATEC

KIYATEC specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.